Uncertainty About Supply Chain Keeps Baxter Out Of Heparin Market
This article was originally published in The Tan Sheet
Executive Summary
Baxter International is unsure whether it will re-enter the Rx blood thinner heparin market due in part to concerns about a "complex and difficult" ingredient supply chain, according to CEO Robert Parkinson